02:27 , Feb 12, 2016 |  BC Extra  |  Top Story

McConnell schedules vote on Califf confirmation

U.S. Senate Majority Leader Mitch McConnell (R-Ky.) has set in motion a procedure that could lead to a vote to confirm Robert Califf as FDA commissioner. On Thursday, McConnell scheduled a vote for Feb. 22...
02:48 , Feb 2, 2016 |  BC Extra  |  Politics & Policy

FDA blocks import of genetically modified salmon

FDA said it will block the importation any food containing genetically engineered salmon. FDA approved genetically engineered AquAdvantage Salmon from AquaBounty Technologies Inc. (LSE:ABTU) in November 2015, but is barred from allowing the fish's sale...
08:00 , Feb 1, 2016 |  BioCentury  |  Politics, Policy & Law

Opioids clouding Califf's tenure

The backlash against confirming Robert Califf as FDA commissioner will color ongoing user fee negotiations, influence FDA's reviews of pending applications for opioid drugs, and intensify pressures on the agency to respond to political pressures...
01:38 , Nov 21, 2015 |  BC Extra  |  Company News

FDA approves genetically modified salmon

FDA approved AquAdvantage Salmon from AquaBounty Technologies Inc. (LSE:ABTX). The Atlantic salmon is genetically engineered to reach market size more quickly than non-genetically engineered farm-raised Atlantic salmon. FDA said the salmon may be raised only...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Company News

AquaBounty, Intrexon deal

Intrexon and aquaculture company AquaBounty partnered to use Intrexon's UltraVector synthetic biology platform to research, develop and manufacture products to increase productivity of the aquaculture industry. Under the deal, which is subject to shareholder approval,...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

AquaBounty, Intrexon deal

AquaBounty said that Intrexon did not receive the 50% of outstanding shares necessary to complete its tender offer of AquaBounty. Intrexon, which holds a 47.56% stake, will not acquire the shares tendered in the offer...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

AquaBounty, Intrexon deal

AquaBounty said Chairman Richard Clothier and Richard Huber, a non-executive director, have informed the company's board they will not tender their shares for an offer from Intrexon to acquire the 52.4% of AquaBounty it does...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

AquaBounty, Intrexon deal

Synthetic biology company Intrexon will acquire a 48% stake in AquaBounty from Linnaeus Capital Partners and its Tethys Ocean B.V. affiliate followed by a tender offer to acquire the rest of the company. The initial...
08:00 , Feb 5, 2007 |  BioCentury  |  Finance

AIM iceberg

AIM iceberg Company Date Raised Post-$ Mcap 12/29/06 Chg York Pharma (LSE:YRK) 4/16/04 £1.0 £2.3 £23.2 932% Lipoxen (LSE:LPX) 1/17/06 £3.8 £13.1 £35.4 169% Vectura (LSE:VEC) 6/25/04 £20.0 £60.0 £156.8 161% ReNeuron (LSE:RENE) 8/5/05 £9.5...
07:00 , Oct 2, 2006 |  BioCentury  |  Finance

IPO performance

IPO performance North America Company Date Raised Post-$ 9/29 Mcap Chg Omrix (OMRI) 4/20/06 $39.5 $148.3 $279.3 88% Acorda (ACOR) 2/10/06 $36.5 $117.7 $179.5 53% Novacea (NOVC) 5/9/06 $44.9 $149.4 $173.5 16% Altus (ALTU) 1/26/06...